MAIA Biotechnology Valuation
| MAIA Stock | USD 2.00 0.06 3.09% |
Based on Macroaxis valuation methodology, the entity appears to be undervalued. MAIA Biotechnology secures a last-minute Real Value of $4.45 per share. The latest price of the entity is $2.0. Our model forecasts the value of MAIA Biotechnology from examining the entity fundamentals such as Shares Owned By Insiders of 19.81 %, return on asset of -1.48, and Current Valuation of 77.62 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting MAIA Biotechnology's valuation include:
Undervalued
Today
Please note that MAIA Biotechnology's price fluctuation is very risky at this time. Calculation of the real value of MAIA Biotechnology is based on 3 months time horizon. Increasing MAIA Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since MAIA Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MAIA Stock. However, MAIA Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.0 | Real 4.45 | Target 12.14 | Hype 2.1 | Naive 1.74 |
The real value of MAIA Stock, also known as its intrinsic value, is the underlying worth of MAIA Biotechnology Company, which is reflected in its stock price. It is based on MAIA Biotechnology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of MAIA Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of MAIA Biotechnology helps investors to forecast how MAIA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MAIA Biotechnology more accurately as focusing exclusively on MAIA Biotechnology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use MAIA Biotechnology's intrinsic value based on its ongoing forecasts of MAIA Biotechnology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against MAIA Biotechnology's closest peers. If more than one evaluation category is relevant for MAIA Biotechnology we suggest using both methods to arrive at a better estimate.
MAIA Biotechnology Cash |
|
MAIA Biotechnology Total Value Analysis
MAIA Biotechnology is now forecasted to have valuation of 77.62 M with market capitalization of 71.84 M, debt of 6.52 M, and cash on hands of 8.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MAIA Biotechnology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
77.62 M | 71.84 M | 6.52 M | 8.15 M |
MAIA Biotechnology Asset Utilization
One of the ways to look at asset utilization of MAIA is to check how much profit was generated for every dollar of assets it reports. MAIA Biotechnology secures a negative usage of assets of -1.48 %, losing $0.0148 for each dollar of assets held by the entity. Ineffective asset utilization conveys that the company is being less productive with each dollar of assets it secures. Strictly speaking, asset utilization of MAIA Biotechnology shows how unsuccessful it operates for each dollar spent on its assets.MAIA Biotechnology Profitability Analysis
Based on the key profitability measurements obtained from MAIA Biotechnology's financial statements, MAIA Biotechnology may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess MAIA Biotechnology's ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-09-30 | Previous Quarter -5.3 M | Current Value -8.9 M | Quarterly Volatility 2.2 M |
For MAIA Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MAIA Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MAIA Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MAIA Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MAIA Biotechnology over time as well as its relative position and ranking within its peers.
MAIA Biotechnology Earnings per Share Projection vs Actual
By analyzing MAIA Biotechnology's earnings estimates, investors can diagnose different trends across MAIA Biotechnology's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for MAIA Biotechnology is based on EPS before non-recurring items and includes expenses related to employee stock options.MAIA Biotechnology Ownership Allocation
MAIA Biotechnology maintains a total of 37.03 Million outstanding shares. MAIA Biotechnology secures 19.81 % of its outstanding shares held by insiders and 6.63 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the entity is less than the current market value, you may not be able to make money on it.MAIA Biotechnology Profitability Analysis
Net Loss for the year was (23.25 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates MAIA Biotechnology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in MAIA Biotechnology and how it compares across the competition.
About MAIA Biotechnology Valuation
The stock valuation mechanism determines MAIA Biotechnology's current worth on a weekly basis. Our valuation model uses a comparative analysis of MAIA Biotechnology. We calculate exposure to MAIA Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MAIA Biotechnology's related companies.MAIA Biotechnology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 22.2 M | |
| Shares Float | 32.1 M |
MAIA Biotechnology Current Valuation Indicators
Valuation refers to the process of determining the present value of MAIA Biotechnology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value MAIA we look at many different elements of the entity such as MAIA's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as MAIA Biotechnology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use MAIA Biotechnology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes MAIA Biotechnology's worth.Complementary Tools for MAIA Stock analysis
When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |